WO2006006718A1 - ステロイド化合物の製造方法 - Google Patents
ステロイド化合物の製造方法 Download PDFInfo
- Publication number
- WO2006006718A1 WO2006006718A1 PCT/JP2005/013216 JP2005013216W WO2006006718A1 WO 2006006718 A1 WO2006006718 A1 WO 2006006718A1 JP 2005013216 W JP2005013216 W JP 2005013216W WO 2006006718 A1 WO2006006718 A1 WO 2006006718A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- following formula
- hydrogen atom
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 115
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 95
- 150000003431 steroids Chemical class 0.000 title claims abstract description 20
- 150000002148 esters Chemical class 0.000 claims abstract description 103
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 100
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 32
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 25
- 230000002829 reductive effect Effects 0.000 claims abstract description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229930182558 Sterol Natural products 0.000 claims abstract description 18
- 235000003702 sterols Nutrition 0.000 claims abstract description 18
- 238000006317 isomerization reaction Methods 0.000 claims abstract description 16
- 125000004185 ester group Chemical group 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims description 153
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 75
- -1 steroid compound Chemical class 0.000 claims description 74
- 125000004432 carbon atom Chemical group C* 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 229960001124 trientine Drugs 0.000 claims description 53
- 125000005843 halogen group Chemical group 0.000 claims description 48
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 45
- 239000004593 Epoxy Substances 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 239000003054 catalyst Substances 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 28
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 24
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 23
- 229960001661 ursodiol Drugs 0.000 claims description 22
- 150000007513 acids Chemical class 0.000 claims description 20
- 229910052763 palladium Inorganic materials 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 20
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000741 silica gel Substances 0.000 claims description 17
- 229910002027 silica gel Inorganic materials 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 238000006460 hydrolysis reaction Methods 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 239000002585 base Substances 0.000 claims description 13
- 125000003700 epoxy group Chemical group 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 125000001033 ether group Chemical group 0.000 claims description 12
- 239000007800 oxidant agent Substances 0.000 claims description 12
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 11
- 238000006735 epoxidation reaction Methods 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 238000005984 hydrogenation reaction Methods 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 150000004703 alkoxides Chemical class 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 230000001590 oxidative effect Effects 0.000 claims description 10
- 150000004965 peroxy acids Chemical class 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 238000010276 construction Methods 0.000 claims description 8
- 229910000510 noble metal Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 150000007514 bases Chemical class 0.000 claims description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 7
- 150000002009 diols Chemical group 0.000 claims description 7
- 125000000468 ketone group Chemical group 0.000 claims description 7
- 150000001451 organic peroxides Chemical class 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 6
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 5
- DNEXRQSSNZPAJJ-UHFFFAOYSA-N 2-methylbenzenecarboperoxoic acid Chemical compound CC1=CC=CC=C1C(=O)OO DNEXRQSSNZPAJJ-UHFFFAOYSA-N 0.000 claims description 5
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 150000001735 carboxylic acids Chemical class 0.000 claims description 5
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 claims description 5
- CMMUKUYEPRGBFB-UHFFFAOYSA-L dichromic acid Chemical compound O[Cr](=O)(=O)O[Cr](O)(=O)=O CMMUKUYEPRGBFB-UHFFFAOYSA-L 0.000 claims description 5
- KIQFUORWRVZTHT-PBDHEXIJSA-N (4r)-4-[(8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound C1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 KIQFUORWRVZTHT-PBDHEXIJSA-N 0.000 claims description 4
- KNVADAPHVNKTEP-YVSSALOQSA-N (4r)-4-[(8r,9s,10s,13r,14s,17r)-7-hydroxy-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound OC1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 KNVADAPHVNKTEP-YVSSALOQSA-N 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 claims description 4
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 150000003460 sulfonic acids Chemical class 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 3
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 3
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 3
- IOOKJGQHLHXYEF-FFFIEFPASA-N 3,7-Diketocholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)CC[C@@H]3[C@]21C IOOKJGQHLHXYEF-FFFIEFPASA-N 0.000 claims description 2
- WOESMZIBKZXASE-UHFFFAOYSA-N N-(2,4-dioxoimidazolidin-1-yl)acetamide Chemical group C(C)(=O)NN1C(NC(C1)=O)=O WOESMZIBKZXASE-UHFFFAOYSA-N 0.000 claims description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- 229960002317 succinimide Drugs 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 2
- NXUBLCILQTXVGB-UHFFFAOYSA-N 1,3-dioxolane-2-carboxylic acid Chemical class OC(=O)C1OCCO1 NXUBLCILQTXVGB-UHFFFAOYSA-N 0.000 claims 1
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000004020 conductor Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical group C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 abstract description 15
- 150000003432 sterols Chemical class 0.000 abstract description 13
- 238000007248 oxidative elimination reaction Methods 0.000 abstract description 11
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 abstract description 4
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 abstract description 4
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 abstract description 2
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 abstract description 2
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 abstract description 2
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 abstract description 2
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 abstract description 2
- INDVLXYUCBVVKW-PXBBAZSNSA-N 24-methylenecholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(=C)C(C)C)[C@@]1(C)CC2 INDVLXYUCBVVKW-PXBBAZSNSA-N 0.000 abstract 1
- UTXLOPQCWLMVMN-UHFFFAOYSA-N 3alpha,16beta-Dihydroxy-5alpha-androstan-7-on Natural products CC1(CCC2C(=CCC3C(C)(CO)C(O)CCC23C)C1)C(O)COC4OC(CO)C(O)C(O)C4O UTXLOPQCWLMVMN-UHFFFAOYSA-N 0.000 abstract 1
- RUSSPKPUXDSHNC-DDPQNLDTSA-N 7-dehydrodesmosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H](CCC=C(C)C)C)CC[C@H]33)C)C3=CC=C21 RUSSPKPUXDSHNC-DDPQNLDTSA-N 0.000 abstract 1
- INDVLXYUCBVVKW-UHFFFAOYSA-N Methylencholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=C)C(C)C)C1(C)CC2 INDVLXYUCBVVKW-UHFFFAOYSA-N 0.000 abstract 1
- ZEPNVCGPJXYABB-UHFFFAOYSA-N UNPD5911 Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(=C)C(C)C)CCC33)C)C3=CC=C21 ZEPNVCGPJXYABB-UHFFFAOYSA-N 0.000 abstract 1
- ZEPNVCGPJXYABB-LOIOQLKMSA-N ergosta-5,7,24(28)-trien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@H]33)C)C3=CC=C21 ZEPNVCGPJXYABB-LOIOQLKMSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 102
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 229940125898 compound 5 Drugs 0.000 description 12
- 150000002576 ketones Chemical class 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 229940126214 compound 3 Drugs 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 150000002170 ethers Chemical class 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000010265 sodium sulphite Nutrition 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000007810 chemical reaction solvent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 4
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 3
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 238000006036 Oppenauer oxidation reaction Methods 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 3
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000006894 reductive elimination reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000009849 vacuum degassing Methods 0.000 description 3
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N Methyl ethyl ketone Natural products CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000012269 metabolic engineering Methods 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- ZKGCEXPUCJDWMB-ZPMVHPDISA-N (4r)-4-[(8r,9s,10s,13r,14s,17r)-10,13-dimethyl-7-oxo-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound C1CCCC2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)CC[C@@H]3[C@]21C ZKGCEXPUCJDWMB-ZPMVHPDISA-N 0.000 description 1
- LKPGRAYVMISUJW-NWXCRLPFSA-N (8S,9S,10R,13S,14S,17R)-16-hydroxy-13-methyl-7-oxo-17-[(2R)-pentan-2-yl]-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-10-carboxylic acid Chemical compound C1CCCC2CC(=O)[C@H]3[C@@H]4CC(O)[C@H]([C@H](C)CCC)[C@@]4(C)CC[C@@H]3[C@]21C(O)=O LKPGRAYVMISUJW-NWXCRLPFSA-N 0.000 description 1
- QRQWWWVRQOKPKO-GYKMGIIDSA-N (8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylhept-5-en-2-yl]-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 QRQWWWVRQOKPKO-GYKMGIIDSA-N 0.000 description 1
- JBSSIYVUAQDIMG-VLWWAJHTSA-N (9s,10r,13r,14r,17r)-17-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-1,2,6,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CCC2=C1 JBSSIYVUAQDIMG-VLWWAJHTSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- SXNYYEPTQTZOHG-UHFFFAOYSA-N 1,8-diazacyclotetradecane-2,7-dione Chemical compound O=C1CCCCC(=O)NCCCCCCN1 SXNYYEPTQTZOHG-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- VMNRNUNYBVFVQI-UHFFFAOYSA-N 10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one Chemical class C1CC2CC(=O)CCC2(C)C2C1C1CCCC1(C)CC2 VMNRNUNYBVFVQI-UHFFFAOYSA-N 0.000 description 1
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OOOLDNHDRZFDFS-UHFFFAOYSA-N CCOO[SiH2]C Chemical compound CCOO[SiH2]C OOOLDNHDRZFDFS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- WXAYTPABEADAAB-UHFFFAOYSA-N Oxyphencyclimine hydrochloride Chemical compound Cl.CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 WXAYTPABEADAAB-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- PHENPABYBHPABM-UHFFFAOYSA-N acetic acid;octane Chemical compound CC(O)=O.CCCCCCCC PHENPABYBHPABM-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical group O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WNJYXPXGUGOGBO-UHFFFAOYSA-N magnesium;propan-1-olate Chemical compound CCCO[Mg]OCCC WNJYXPXGUGOGBO-UHFFFAOYSA-N 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- HKJYVRJHDIPMQB-UHFFFAOYSA-N propan-1-olate;titanium(4+) Chemical compound CCCO[Ti](OCCC)(OCCC)OCCC HKJYVRJHDIPMQB-UHFFFAOYSA-N 0.000 description 1
- CZPZWMPYEINMCF-UHFFFAOYSA-N propaneperoxoic acid Chemical compound CCC(=O)OO CZPZWMPYEINMCF-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- MDDPTCUZZASZIQ-UHFFFAOYSA-N tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] MDDPTCUZZASZIQ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Definitions
- the present invention relates to a method for producing a steroid compound, and more specifically, by reducing and saturating a steroid compound having a double bond at the 4-position to construct a 5 i3 steric compound, 5 ⁇ -3,7-dioxocoranoic acid or Regarding the method of producing the ester derivative, more specifically, Cholester 5, 7, 24-trien _ 3) 3-ol, or ergoster 5, which is a sterol having a double bond at the 5-position and the 24-position, 7, 24 (2 8) One Trien 3] 3—All, Desmosterol or Fucostello Norre, El Goster 5, 24 (28) —Gen 1 3
- the present invention is based on a chemical synthesis method using coreester 5,7,24-trienone 3 i3-ol as a raw material and passing through corester 4,6,24-trien_3-one 5] 3 —
- This invention relates to a method for producing 3,7-dioxocolanic acid or its ester derivatives.
- This ester derivative of 5 ⁇ -3,7-dioxocoranic acid is useful as a synthetic intermediate for pharmaceuticals such as ursodeoxycholic acid and chenodeoxycholic acid.
- the present invention further relates to a process for producing Cholester 4, 6, 24-trien-3-one using Cholester 5, 7, 24_trien 3_ol as a raw material.
- This product Is useful as a synthetic intermediate for various steroid drugs.
- 5 3-3,7-Dioxocolanic acid or its ester derivatives can be produced from raw materials with the same skeleton and the same carbon number such as benoic acid-derived kenodeoxycholic acid and ursodeoxycholic acid.
- benoic acid-derived kenodeoxycholic acid and ursodeoxycholic acid for example, JP 52-78644, JP 52-78863, Spanish Patent 489661, French Patent 2453182, Japan Chemical Journal 19 55, 76 ⁇ , 297, and J. Chem. Soc., Perkin. 1, 1990, 1 ⁇ , 1)).
- these ketodeoxycholic acid and ursodeoxycholic acid are also reported.
- (1) is derived from natural raw materials and is expensive, and there are difficulties in obtaining a sufficient quantity, and the establishment of an inexpensive chemical synthesis method has been desired.
- (2) and (3) are derived from natural sources as in (1) and are expensive, and there is a process for adjusting the number of carbons in the side chain to the desired compound. The number of processes is very large, such as the need for multi-stage acidification processes for the introduction of functional groups.
- a 3-oxo-1,4-diene steroid compound is used as a method for introducing an oxygen functional group at the 7-position of a sterolide compound.
- a 3-oxo-1,4-diene steroid compound is used as a method for introducing an oxygen functional group at the 7-position of a sterolide compound. It shows how to epoxidize to 3_oxo-4-ene-6,7-epoxy sterolide compounds, for example
- Appl. Environ. Microbiol., 1986, 51 ⁇ , p. 946 a method to convert 3-oxo-4-ene steroid compounds into 3-oxo-4-ene-7-ol sterolides using microorganisms. It is shown.
- J. Chem. Res., Synop., 1986, No. 2, p. 48 shows a method for converting 3-oxosteroid compounds into 3-oxo-7-ol steroid compounds using microorganisms. ing.
- Appl. Environ. Microbiol., 1982, 44 ⁇ , p. 6 describes a method for converting a 5 ⁇ -13-hydroxysterolide compound into a 5i3-3,7-dihydroxyxteroxide compound using microorganisms. It is shown.
- a method of oxidative cleavage of a double bond for example, a method of cleaving via epoxidation or glycolation of a double bond, a method of cleaving via a ketone, Is known to be directly cleaved by ozone.
- Cholester 4, 6, 24-trien-3-one which is an intermediate when using Cholester 5, 7, 24-trien 1-ol as a raw material, is a synthetic intermediate for various sterol pharmaceuticals.
- the conventional acquisition route is derived from a raw material of natural origin and manufactured through a long reaction process, and its application is limited in terms of cost and quantity. For example, Biochem. Biophys. Res.
- the object of the present invention is to provide a sterol having a double bond at the 5-position and the 24-position, more specifically, Cholester 5, 7, 24-trien _ 3 ol, or Ergosta — 5, 7, 24 (28) —Toren 3 3—Honore, Desmostero or Fu Costello 1 and Enorego Star 5, 24 (28) 1 Gen 3 3 Using i3—Honore as raw materials,
- an oxygen functional group at the 7-position can be achieved by epoxidizing the 6-position double bond in the case of 3-oxo-4,6-diene steroids.
- hydroxylation at the 7-position is possible using microorganisms.
- the present inventors have conducted an arbitrary study to solve the above-mentioned problems.
- a 1 represents a hydrogen atom or an isopropyl group
- a 2 and A 3 each independently represent a methyl group when A 1 is a hydrogen atom, and water when A 1 is an isopropyl group. It represents an elementary atom or a methyl group, and the bond between C 1 and C 11 represents a single bond or a double bond.
- St represents a steroid skeleton composed of A ring, B ring, C ring and D ring, which is bonded to the side chain shown in the formula at (1) C 17 position
- a ring, a B ring, a C ring and a D ring may have a hydroxyl group, a protected hydroxyl group, a keto group or an epoxy group,
- the carbon-carbon bond at one or more positions selected from the group of C 1 position to C 8 position may have a double bond, (4) C4 position, C 10 position, C One or more positions selected from the group of positions 13 and C 14 may be substituted with a methyl group. That is, according to the present invention, the following inventions (1) to (49) are provided.
- (1) Five-dimensional construction by reductive saturation of the 4-position double bond using steroidal compounds with 22 or more carbon atoms (preferably 24 or more) produced by fermentation from carbohydrates as raw materials The following general formula (8), (21 a), (21 b), (21 c) or (21 d)
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- a 1 represents a hydrogen atom or an isopropyl group, and each of A 2, A 3 are independently, A 1 represents a methyl group when the hydrogen atom, hydrogen atom when A 1 is isopropyl or
- B 1 and B 2 and B 3 each independently represents a hydroxyl group or a protected hydroxyl group, and n represents an integer of 0 or 1.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- a 1 represents a hydrogen atom or an isopropyl group, and each of A 2, A 3 are independently, A 1 represents a methyl group when the hydrogen atom, hydrogen atom when A 1 is isopropyl or Represents a methyl group, B 1 and B 2 and B 3 each independently represent a hydroxyl group or a protected hydroxyl group, and n represents an integer of 0 or 1.
- a 1 represents a hydrogen atom or an isopropyl group, and each of A 2, A 3 are independently, A 1 represents a methyl group when the hydrogen atom, hydrogen atom when A 1 is isopropyl or A methyl group, and a bond between C z and C 11 is a single bond or a double bond).
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- a 1 represents a hydrogen atom or an isopropyl group
- a 2 and A 3 are independent of each other.
- a 1 is a hydrogen atom, it represents a methyl group
- a 1 is an isopropyl group
- it represents a hydrogen atom or a methyl group
- the bond between C t and C 11 represents a single bond or a double bond.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- a 1 represents a hydrogen atom or an isopropyl group, and each of A 2, A 3 are independently, A 1 represents a methyl group when the hydrogen atom, hydrogen atom when A 1 is isopropyl or a methyl group
- C Suteronore compound is between ⁇ 11 binding represented by shown to) a single bond or a double bond, Kore star 5, 7, 24 - Toryen 3 beta one-ol or ergosta _ 5,, 7 , 24 (2 8) 1 triene 1 3 ⁇ -ol, Desmostello 1 or Fucostello 1, Enoregostar 5, 24 (28) — Gen 3 3 j3 — ol
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- a method for producing a derivative is ursodeoxycholic acid (20 a), Kenodeoxycholic acid (2 O b) or 5 j3-3 ⁇ -hydroxy mono 7-ketocholanoic acid (20 c), 5 j3-7-hydroxy mono 3-ketocholanic acid (20 d) or esters of these acids.
- a 1 represents a hydrogen atom or an isopropyl group, and each of A 2, A 3 are independently, A 1 represents a methyl group when the hydrogen atom, hydrogen atom when A 1 is isopropyl or a methyl group, C: ⁇ 11 between binding sterol compounds represented by shown to) a single bond or a double bond, Kore star 5, 7, 24 Toryen _ 3 is an all-in (4)
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- a method for producing an ester derivative is ursodeoxycholic acid (2 1 a) Kenodeoxycholic acid (2 1 b) or 5 i3-3 ⁇ -hydroxy-l 7-ketocholanoic acid (2 1 c), 5 7-hydroxy-3-ketocholanic acid (2 1 d) or any of these acids.
- the basic compound is an alkali metal or alkaline earth metal hydroxide, carbonate or alkoxide, wherein Cholester 4, 6, 24-trien-3-one according to (11) Manufacturing method.
- R 4 to R 8 are each independently a hydrogen atom, a protected hydroxyl group or a halogen atom, or a carbonyl group, an ether group, a protected hydroxyl group, a halogen atom or a force loxyl group. Represents an optionally substituted alkyl group having 1 to 10 carbon atoms, an alkenyl group or an alkynyl group.
- a 3-hydroxy-5,7-diene steroid compound represented by the following general formula (3a), (3 b), (3 c), (3 d), (3 e)
- R 4 to R 8 are each independently substituted with a hydrogen atom, a protected hydroxyl group or a halogen atom, or a carbonyl group, an ether group, a protected hydroxyl group, a halogen atom or a carboxyl group.
- a method for producing a 3-oxo-1,4-diene steroid compound characterized in that the method is carried out in the presence of a ketone compound and a metal alkoxide while blocking oxygen.
- (1 6) The following general formula (3 a), (3 b), (3 c), (3 d) or (3 e)
- R 4 to R 8 are each independently a hydrogen atom, a hydroxyl group, a protected hydroxyl group or a halogen atom, or a carbonyl group, an ether group, a hydroxyl group, a protected hydroxyl group, a halogen atom or a carboxyl group.
- R 4 to R 8 are each independently a hydrogen atom, a hydroxyl group, a protected hydroxyl group or a halogen atom, or a carbo group, an ether group, a hydroxyl group, a protected hydroxyl group, a halogen atom or a carboxyl group.
- -oxo _ 4, 6- A method for producing a diene steroid compound.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- the following general formula (8) is characterized in that it is converted to 5 / 3-cholester 3-one-7, 24, 25-triol, and is further oxidized and optionally esterified.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- (21) A method for producing 5] 3-3,7-dioxocoranoic acid or an ester derivative thereof according to any one of (17) to (20), wherein an organic peroxide is used as an epoxidizing agent .
- a 6 and A 7 each independently represents an alkyl group having 1 to 20 carbon atoms which may be substituted by halogen, or A 6 and A 7 are bonded to form a cyclic group having 3 to 8 carbon atoms.
- Trien 3-one is haloesterified
- a noble metal catalyst powdered a palladium or activated carbon carrying palladium palladium content is from 0.5 to 50 weight 0/0, aluminum oxide carrying palladium charcoal barium ⁇ palladium, or barium sulfate-supported palladium
- a noble metal catalyst powdered a palladium or activated carbon carrying palladium palladium content is from 0.5 to 50 weight 0/0, aluminum oxide carrying palladium charcoal barium ⁇ palladium, or barium sulfate-supported palladium
- metallic palladium selected from the group consisting of palladium on carbonic acid and lithium are used.
- the method for producing 5 3-3,7-dioxocoranoic acid or an ester derivative thereof according to (28) .
- R 8 is a hydroxyl group, a protected hydroxyl group, a carboxyl group, an ester group, a carbo group, a cyan group, an amino group, or an alkyl group having 1 to 20 carbon atoms which may be substituted with a halogen atom.
- R 8 is a hydroxyl group, a protected hydroxyl group, a carboxyl group, an ester group, a carbonyl group, a cyano group, an amino group, or an alkyl group having 1 to 20 carbon atoms which may be substituted with a halogen atom, -Represents a diol group or an alkyl group).
- St represents a steroid skeleton composed of A ring, B ring, C ring and D ring, which is bonded to the side chain shown in the formula at (1) C 17 position
- R 9 has a hydroxyl group, a protected hydroxyl group, a carboxyl group, an ester group, a carbonyl group, a cyano group, an amino group, or a halogen atom.
- St represents a steroid skeleton composed of A ring, B ring, C ring and D ring, and the steroid skeleton is bonded to the side chain shown in the formula at (1) C 17 position
- a ring, a B ring, a C ring and a D ring may have a hydroxyl group, a protected hydroxyl group, a keto group or an epoxy group,
- the carbon-carbon bond at one or more positions selected from the group of C 1 position to C 8 position may have a double bond, (4) C4 position, C 10 position, C One or more positions selected from the group of positions 13 and C 14 may be substituted with a methyl group.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- Cholester 5, 7, 24, -trien 3 3 -ol which is a raw material for the production method of the present invention, is a substance known per se. For example, it can be produced by culturing a mutant strain produced by altering metabolic engineering of a fungus that produces ergosterol via timosterol and collecting it from the culture.
- this production method for example, the methods described in JP-A Nos. 5-19 2 1 8 4 and 2 0 4-14 1 4 1 2 5 can be referred to.
- Step 1 of the present invention involves the formation of the 3-position hydroxyl group of Cholester 5, 7, 24-trien- 3 J3-ol (hereinafter sometimes referred to as “compound 2”). Oxidation and isomerization of the 5-position double bond to the 4-position are performed simultaneously. This is known as a conversion method from ergosterol to ergosterone, and is called “oppenauer oxidation”.
- This oxidation reaction is performed using a metal alkoxide as a catalyst and a keton compound as a hydrogen acceptor.
- a metal alkoxide for example, aluminum isopropoxide, aluminum tert-butoxide, magnesium ethoxide, magnesium propoxide, titanium propoxide and the like are used.
- R 2 and R 3 may be bonded to each other to form a cyclic structure having 3 to 8 carbon atoms.
- a compound represented by the following formula is used, specifically, acetone, methyl iso Butyl ketone, methylisobutyl Chain ketones such as ketones and cyclic ketones such as cyclohexanone and cyclopentanone are used.
- aluminum isopropoxide is used as a catalyst
- cyclohexanone or methyl isobutyl ketone is used as a ketone compound.
- the amount of the catalyst to be used is generally about 0.1 to 20 mol, preferably about 0.2 to 0.5 mol, per 1 mol of “Compound 1”.
- the hydrogen acceptor is usually used in an amount of 1 to 50 mol, preferably about 2 to 10 mol, per mol of “Compound 1”.
- This reaction can be carried out without solvent, but a solvent may be used.
- solvents include aliphatic hydrocarbons such as hexane, aromatic hydrocarbons such as toluene, halogenated solvents such as dichloromethane, ethers such as jetyl ether and tetrahydrofuran, dimethylsulfoxide and dimethylformamide.
- An aprotic polar solvent such as copper can be used.
- an aprotic solvent is used, and more preferably, toluene or heptane is used.
- the reaction temperature is usually 90 to 130 ° C, preferably 100 to 120 ° C, and the reaction time is about 1 to 3 hours.
- Compound 2 After completion of the reaction, cool to room temperature and deactivate the catalyst by adding water. The deposited precipitate is filtered, and the filtrate is concentrated to obtain Cholester 4, 7, 2 24 1-trien 3_one (compound 2) as the target product. Compound 2 can be further isolated and purified by a method such as crystallization by gel force ram chromatography or crystallization.
- this reaction is preferably carried out under oxygen interruption from the viewpoint of product stability.
- a solvent or ketone compound is previously deoxygenated, and the reaction is carried out in a nitrogen or argon atmosphere.
- the reaction is carried out in a nitrogen atmosphere by using a method of degassing the solvent and ketone compound under reduced pressure and substituting with nitrogen, or a method of substituting nitrogen by heating and refluxing under nitrogen.
- the isomerization reaction of the present invention comprises the following general formulas (2 a), (2 b), (2 c), (2 d), (2 e)
- R 4 to R 8 are each independently a hydrogen atom, a protected hydroxyl group or a halogen atom, or a carbo group, an ether group, a protected hydroxyl group, a halogen atom or a carboxyl group.
- R 4 and R 6 to R 8 are each independently a hydrogen atom, a protected hydroxyl group or a halogen atom, or a carbonyl group, an ether group, a protected hydroxyl group, or a halogen atom. Or a C1-C10 alkyl group, alkenyl group or alkynyl group optionally substituted with a carboxyl group, which can be oxidized in a high yield.
- Specific examples of the compound (2a) include Cholester 5, 7, 24-trien _3 —ol, and enoregostero monore.
- Step 2 of the present invention involves the 7-position double bond of Cholester 4, 7, 24 — Trien 3 _ 1 (hereinafter sometimes abbreviated as “Compound 3”).
- This is a reaction that isomerizes to the 6-position.
- the isomerization reaction is performed using a basic compound as a catalyst.
- Such basic compounds include alkali metal hydroxides, alkaline earth metal hydroxides, alkali metal carbonates, alkaline earth metal carbonates, alkali metal bicarbonates, alkali metal acetates, alkaline earths.
- Alkali metal acetates, alkaline metal alkoxides or alkaline earth metal alkoxides are used, preferably alkali metal hydroxides are used, and more preferably hydrolysable lithium and sodium hydroxide. .
- the amount of the basic compound used is usually about 1 to 20 mol, preferably about 2 to 10 mol, per 1 mol of “Compound 2”.
- the reaction solvent is not particularly limited, but aliphatic hydrocarbons such as hexane, aromatic hydrocarbons such as toluene, halogenated solvents such as dichloromethane, ethers such as jetyl ether and tetrahydrofuran, alcohols such as methanol and ethanol An aprotic polar solvent such as dimethylsulfoxide or dimethylformamide can be used, and methanol is preferably used.
- the reaction is usually carried out at 40 to 80 ° C, preferably 50 to 70 ° C for about 5 to 10 hours.
- acid is added to neutralize the base used as a catalyst and stop the reaction.
- the acid to be used is not particularly limited.
- mineral acids such as hydrochloric acid and sulfuric acid
- organic carboxylic acids such as formic acid and acetic acid
- organic sulfonic acids such as p-toluenesulfonic acid
- the solvent may be distilled off under reduced pressure to obtain the target product, cholester 4, 6, 24,4-trien-3-one (hereinafter sometimes abbreviated as “compound 3”). it can.
- compound 3 cholester 4, 6, 24,4-trien-3-one
- water is added to the reaction solution after the neutralization treatment to crystallize compound 3, or an organic solvent is added to extract, and the organic solvent phase is washed with water, dried, concentrated, and silica gel column chromatography. It can be isolated and purified by one or other methods.
- this reaction is preferably carried out under oxygen interruption from the viewpoint of substrate stability.
- the solvent is previously deoxygenated and the reaction is carried out in a nitrogen or argon atmosphere.
- the reaction is carried out in a nitrogen atmosphere using a method of degassing the solvent under reduced pressure and replacing with nitrogen, or a method of replacing with nitrogen by heating under reflux under nitrogen.
- the isomerization reaction of the present invention is carried out by the following general formula (3 a), (3 b), (3 c), (3 d), or (3 e)
- R 4 to R 8 are each independently a hydrogen atom, a hydroxyl group, a protected hydroxyl group or a halogen atom, or a carbonyl group, an ether group, a hydroxyl group, a protected hydroxyl group, a halogen atom or a carboxyl group.
- R 4 to R 8 are each independently a hydrogen atom, a hydroxyl group, a protected hydroxyl group or a halogen atom, or a carbonyl group, an ether group, a hydroxyl group, a protected hydroxyl group, a halogen atom or a carboxyl group.
- Examples of the protected hydroxyl group include a hydroxyl group protected with an ether-based protecting group.
- Step 3 of the present invention is the 6th position of Cholester 4, 6, 24 — Trien-3-one (hereinafter sometimes abbreviated as “Compound 4”).
- This reaction epoxidizes the double bond at the 24 position.
- An organic peroxide is usually used as the epoxidizing agent.
- a 4 C0 3 H As the organic peroxide, a general formula A 4 C0 3 H (wherein A 4 is a hydrogen atom, an alkyl group having 1 to 20 carbon atoms which may be substituted by a halogen atom, or an aryl having an optional substituent.
- a percarboxylic acid represented by) or a general formula A 5 (C NH) OO H (wherein A 5 represents a hydrogen atom, an alkyl group having 1 to 20 carbon atoms which may be halogen-substituted, or an aryl group which may have a substituent).
- a 6 and A 7 each independently represents an alkyl group having 1 to 20 carbon atoms which may be substituted by halogen, or A 6 and A 7 are bonded to form a cyclic group having 3 to 8 carbon atoms.
- a dioxysilane derivative represented by the following formula may be used.
- percarboxylic acids include performic acid, peracetic acid, perpropionic acid, perbenzoic acid, 2-methylperbenzoic acid, monoperphthalic acid, and the like
- dioxysilane derivative include dimethyldioxysilane (aceton peroxide), methylethyldioxysilane (methylethyl ketone ketone) and the like.
- reaction selectivity it is particularly preferable to use perbenzoic acid or 2-methylperbenzoic acid.
- the amount of the organic peroxide to be used is generally 2 to 10 molar equivalents, preferably 2 to 3 molar equivalents, relative to 1 mol of “Compound 4”.
- the temperature of epoxidation is usually selected from the range of 0 to 100 ° C, preferably 40 to 90 ° C.
- the reaction solvent is not particularly limited, but aliphatic hydrocarbons such as hexane, aromatic hydrocarbons such as toluene, halogen solvents such as dichloromethane, ethers such as jetyl ether and tetrahydrofuran, ethyl acetate and butyl acetate, etc.
- Esters, nitriles such as acetonitrile, alcohols such as methanol and ethanol, aprotic polar solvents such as dimethylsulfoxide and dimethylformamide, and water can be used. Preferred are esters.
- Step 3 B of the present invention is a reaction for epoxidizing the double bond at position 24 of Cholester 4, 6, 24, 4-trien-3-one (Compound 4). is there.
- the double bond at the 24th position takes precedence, and then the double bond at the 6th position is epoxidized. Therefore, if the amount of the epoxy agent used is small and the reaction temperature is low, it becomes a monoepoxy compound in which only the double bond at the 24-position represented by the formula (10) is epoxidized. So, for example, the amount of epoxidizing agent used
- Step 3C Cholester 4,4—Gen-1-3-one 24, 25-diol represented by the following formula (11) 6,7-epoxy cholesterol 4 represented by the following formula (9) 3-on-one 24, 25-diol production process.
- Step 3C of the present invention epoxidizes the double bond at the 6-position of cholester 4,6-gen-3-one _24,25-diol (compound 11). The reaction is performed.
- a method for obtaining the diepoxy compound (5) a method in which hydrolysis of an ester and ring closure to an epoxy group are combined via a double ester is also possible.
- the haloesterification is represented by an organic carboxylic acid and a general formula Z—X (wherein X represents a halogen atom, Z represents succinic acid imide, phthalenoimide, acetamido, hydantoin, or t-butoxy group).
- a halocation generator is preferably used, and organic power is preferably formic acid as sulfonic acid, and tert-butyl neopolychloride as halocation generator.
- the amount of the organic carboxylic acid to be used is generally 2 to 50 mol, preferably 2 to 10 mol, per 1 mol of “Compound 4”.
- the amount of the halocation generator to be used is generally 2 to 10 mol, preferably 2 to 5 mol, per 1 mol of “Compound 4”.
- reaction temperature is usually from 0 to 50 ° C, preferably from 0 to 30 ° C.
- Reaction solvents include aliphatic hydrocarbons such as hexane, aromatic hydrocarbons such as toluene, halogenated solvents such as dichloromethane, ethers such as jetyl ether and tetrahydrofuran, ethyl acetate and butyl acetate.
- Esters, nitriles such as acetonitrile, ketones such as acetone, and organic carboxylic acids such as acetic acid and formic acid can be used.
- a base is used for hydrolysis of the resulting haloester and ring closure to the epoxy group.
- alkali metal or alkaline earth metal hydroxide, carbonate or alkoxide is used, and the amount used is usually 2 to 50 mol, preferably 4 to 1 with respect to 1 mol of “Compound 15”. 0 mole.
- the reaction temperature is usually in the range of 0 ° C to 50 ° C, preferably 0 to 30 ° C.
- the reaction solvent is not particularly limited.
- alcohols such as methanol and ethanol, ketones such as acetone, nitrinoles such as acetonitrile, and water are used.
- step 4A of the present invention is a double bond hydrogen at the 4-position of 6, 7:24, 25-diepoxycholester 4-en-3-one (compound 5). (Reduction) and reductive cleavage of the 6-position carbon-oxygen bond. Hydrogenation is carried out using hydrogen in the presence of noble metal catalysts such as palladium, platinum, and ruthenium.
- the palladium catalyst activated carbon-supported palladium powder or palladium content of from 0.5 to 50 by weight 0/0, aluminum oxide carrying palladium, carbonate Paris ⁇ beam carrying palladium sulfate Pariumu carrying Palladium or calcium carbonate supported palladium can be used.
- the precious metal catalyst is usually used in an amount of about 0.005 to 0.5 mole per mole of “Compound 5”.
- the hydrogen pressure there is no particular limitation on the hydrogen pressure, but the reaction is usually carried out at a pressure of IMP a or less.
- Solvents may include alcohols, ethers, esters, aliphatic and aromatic hydrocarbons, but are not particularly limited! ,.
- a base is preferably present from the viewpoint of selectivity, and as the base, amines such as pyridine, triethylamine, tetramethylethylenediamine and diisopropylamine are preferable.
- the amount of base used is usually about 0.1 to 100 mol per 1 mol of “Compound 5”.
- the reaction temperature is usually 0 to 50 ° C, preferably 0 to 20 ° C.
- the step 5A of the present invention is an epoxy compound having a 2-4,25-position of 5] 3-2 4,2 25-epoxycholester 3-one-7-ol (compound 6).
- the group is hydrolyzed to 24,25-vidinaldiol.
- the hydrolysis reaction is performed by reacting water in the presence of a catalyst.
- a catalyst peptonic acid or silica gel can be used.
- the protonic acid include hydrochloric acid, sulfuric acid, nitric acid, perchloric acid, phosphoric acid, phosphorous acid, hypophosphorous acid, organic carboxylic acids, and organic sulfonic acids.
- the reaction temperature is usually from 10 to 60 ° C., particularly at room temperature for about 1 to 4 hours, and if necessary, neutralization is performed to separate the target product.
- the reaction solvent is not particularly limited, and esters, ethers, nitriles and the like can be used.
- esters, ethers, nitriles and the like are preferably used.
- the catalyst is used in an amount of about 0.01 to 2 moles per mole of “Compound 6”.
- Compound 5 is adsorbed by passing an organic solvent solution of compound 5 through a gel-like squeezing force, and then passing through an organic solvent again to hydrolyze the 2-4, 25-position epoxy groups of compound 5.
- Compound 7 can also be obtained.
- the resulting 5-cholester-3-one 7, 24, 25-triol (compound 7) can be isolated and purified by silica gel column chromatography or crystallization.
- the process 5 B of the present invention comprises 24, 25-position epoxy groups of 6, 7:24, 25-diepoxycholester 4-en-3-one (compound 5). , which is hydrolyzed to 25-vidinaldiol.
- Step 5C This is the same reaction as in Step 5A described above in terms of hydrolysis reaction of the side chain epoxy of the steroid compound. Therefore, the same catalyst and solvent as in Step 5A can be used, and the reaction conditions are also the same.
- Step 5 C of the present invention comprises 24,25-epoxy cholester 4,6-gen-l-3-one (Compound 10) 24,25-epoxy group 24,25-visidic Hydrolysis to naldiol is performed.
- Step 5A This is the same reaction as in Step 5A described above in terms of hydrolysis reaction of the side chain epoxy of the steroid compound. Therefore, the same catalyst and solvent as in step 5A The reaction conditions are the same.
- step 5D of the present invention is carried out by the steps of 24, 25-position epoxy group 24,25-vidinal of 5_24,25-epoxycholester 3,7-dione (compound 12). Hydrolysis to diol is performed.
- Step 5A This is the same reaction as in Step 5A described above in terms of hydrolysis reaction of the side chain epoxy of the steroid compound. Accordingly, the same catalyst and solvent as in step 5A can be used, and the reaction conditions are also the same.
- Step 4B of the present invention is a double bond at the 4-position of 6,7-epoxycholester 4 ene 3_one 1 24,25-diol (compound 9). Hydrogenation (reduction) and reductive cleavage of 6-position carbon-oxygen bond.
- Step 4A This is the same reaction as in Step 4A described above in terms of hydrogenation of the 6- and 7-position epoxy groups of the steroid B ring. Therefore, the same noble metal catalyst, base and solvent as in step 4A can be used, and the reaction conditions are also the same.
- the step 6A of the present invention comprises acid cleavage of the 2 4,25-diol portion of 5 j3—cholester 3—one-one 7, 2 4, 2 5—triol and The 7-position hydroxyl group is oxidized and, if necessary, an esterification reaction is performed.
- halogen acids or salts thereof molecular halogen, or permanganic acids, dichromic acids, or chromic acids can be used.
- halogen acids chlorine, bromine, iodine hypohalous acid, halous acid, halogen acid or perhalogen acid is used.
- these salts alkali metal salts such as lithium, potassium and sodium, and alkaline earth metal salts such as calcium and magnesium are used.
- hypohalous acid or a salt thereof more preferably, calcium hypochlorite or sodium hypochlorite is used.
- molecular halogens such as chlorine gas and bromine gas can be used as oxidizing agents.
- halogen acids or salts thereof and molecular halogen can be used in combination.
- permanganic acids potassium permanganate is used.
- dichromic acids dichromic acid and its pyridine salt are used.
- chromic acids chromic acid and its picanoic acid are used.
- a lysine salt is used.
- This oxidation reaction is carried out in the presence of a solvent such as ketones, esters, nitriles, ethers, halogenated aliphatic hydrocarbons, halogenated aromatic hydrocarbons, etc. 3 to 20 molar equivalents, preferably 3 to 6 molar equivalents of oxidant, and 0 to 100 ° C, preferably 0 to 30 ° C.
- a solvent such as ketones, esters, nitriles, ethers, halogenated aliphatic hydrocarbons, halogenated aromatic hydrocarbons, etc.
- R can be isolated and purified by silica gel column chromatography or crystallization.
- esterification of the 24th-position carboxylic acid is carried out by a known method, and it is derived into an ester derivative of the same carboxylic acid (in the compound 8, R is an alkyl group having 1 to 6 carbon atoms). It can be isolated and purified by methods such as silica gel column chromatography and crystallization.
- the alcohol used for esterification include linear, branched or cyclic alcohols such as methanol, ethanol, n-butanol, t-butanol, and cyclohexanol. Of these, methanol is preferred.
- the reaction can be easily carried out by heating in an alcohol in the presence of an acid catalyst such as sulfuric acid or p-toluenesulfonic acid. It can also be esterified with a dialkyl sulfate and a base (for example, potassium carbonate) in an organic solvent other than alcohol.
- Step 6 B of the present invention involves oxidation of the 7-position hydroxyl group of 5 1 2 4, 25-epoxycholester 3-one-7-ol (compound 6) to a ketone. Is what you do.
- Step 6A This is the same reaction as in Step 6A described above in terms of the acid-oxidation reaction of the 7-position hydroxyl group of the steroid compound to the ketone. Therefore, the same oxidizing agent and solvent as in Step 6A can be used, and the reaction conditions are the same, but the required oxidizing agent amount is 1 to 5 molar equivalents, preferably 1 to 1 mol per 1 mol of “Compound 6”. 2 molar equivalents.
- Process 6 C > 5 ⁇ -cholester 3,7-dione represented by the following formula (1 3) 2 4 2 5—diol represented by the general formula (8) 5 i3-3,7-dioxocolan Manufacturing process of acid or its ester derivative.
- the step 6C of the present invention comprises oxidation of the 2,4,25-diol part of the five-cholester 3,7-dione-one 2,4,25-diol (compound 1 3). Cleavage is performed.
- Step 6A This is the same reaction as in Step 6A described above in terms of the acid cleavage reaction of the 2,4,25-diol part of the steroid compound. Therefore, the same oxidizing agent and solvent as in Step 6A can be used, and the reaction conditions are the same, but the required oxidizing agent amount is 3 to 10 monoequivalents per mole of “Compound 13”, preferably 2 ⁇ 3 molar equivalents.
- R 8 represents a hydroxyl group, a protected hydroxyl group, a carboxyl group, an ester group, a carboxyl group, a cyan group, an amino group, or an alkyl group having 1 to 20 carbon atoms which may be substituted with a halogen atom.
- an alkenyl group 'or an alkyl group. an epoxy compound represented by the following general formula (1 8):
- St represents a steroid skeleton composed of A ring, B ring, C ring and D ring, and the steroid skeleton includes (1) a side chain shown in the formula at C 17 position.
- the carbon-carbon bond at one or more selected positions may have a double bond, (4) Group of C 4 position, C 10 position, C 13 position and C 14 position One or a plurality of positions selected from may be substituted with a methyl group.
- R 9 represents a hydroxyl group, a protected hydroxyl group, a carboxyl group, an ester group, a carbonyl group, a cyano group, an amino group, or an alkylene group having 1 to 20 carbon atoms which may have a halogen atom, an alkenylene group or an alkynyl group. Rene group is shown. The same can be applied to the sterol epoxy compound represented by
- R 8 is a hydroxyl group, a protected hydroxyl group, a carboxyl group, an ester group, a carbonyl group, a cyano group, an amino group, or an alkyl group having 1 to 20 carbon atoms which may be substituted with a halogen atom
- the steroidal epoxy compound is represented by the following general formula (19):
- St represents a steroid skeleton consisting of A ring, B ring, C ring and D ring, and the steroid skeleton is bonded to the side chain shown in the formula at (1) C 17 position.
- a ring, a B ring, a C ring and a D ring may have a hydroxyl group, a protected hydroxyl group, a keto group or an epoxy group, and (3) C 1 position to C 8 position
- the carbon-carbon bond at one or more positions selected from the group may have a double bond, (4) C 4 position, C 10 position, C 1 position 3 and C 1 position 4
- One or more positions selected from the group may be substituted with a methyl group.
- R 9 is a hydroxyl group, a protected hydroxyl group, a strong lpoxyl group, an ester group, a carbonyl group, a cyano group, an amino group, or an alkylene group having 1 to 20 carbon atoms which may have a halogen atom, an alkenylene group or Indicates an alkylene group. ) Can be converted into vicinal diol compounds represented by
- Examples of the epoxy compound represented by the general formula (1 6) include, for example, an epoxy compound derived from citronol, and examples of the steroidal epoxy compound represented by the general formula (1 8) include 24 4 , 2 5—Epoxy Cholester 4, 6—Gen 3—On, 2 4,2 5—Epoxy Cholester 4 1—3—On, etc.
- the method of the present invention can be applied to these epoxy compounds to It is possible to produce a visual diol.
- the 5 ⁇ -3,7-dioxocoranic acid or its ester derivative (Compound 8) obtained by the method of the present invention is an intermediate of sterolide medicine.
- Compound 8 is reduced by a known method to give the following general formula (2 1 a), (2 1 b), (2 1 c) or (2 1 d)
- R 1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- a reduction method for example, water, methanol, ethanol, tetrahydrofuran or the like is used as a solvent, and nickel (particularly Raney nickel), connort, copper'chromium or the like is present, preferably an aluminum hydroxide or the like.
- nickel particularly Raney nickel
- connort, copper'chromium or the like is present, preferably an aluminum hydroxide or the like.
- Examples include a method of reacting with hydrogen in the presence of force (catalytic hydrogenation method) and a method of reacting with an alkali metal in an alcohol (metal reduction method).
- a method using a specific organoboron compound with tetrahydrofuran as a solvent hydroide reduction method using K-selectride
- the following reaction process can be used.
- JP-A-5 2-7 8 86 3 JP-A 5 2-7 8 8 6 4, JP-A 6 0-2 2 8 5 0 0, Tetrahedron (1984) Reference can be made to the descriptions on pages 40, 5 and 851. ⁇
- both of the sterol having a double bond at the 5-position and the sterol having a double bond at the 5- and 7-positions can be carried out, for example, by the same method as in Step 1.
- a sterol substrate having a double bond at the 6-position can be carried out in the same manner as in Steps 3 to 3, 3 C and Step 7, for example.
- (IV) can be carried out, for example, by the same method as in Steps 4A and 4B.
- the epoxidation of the 24-position double bond is performed in the same manner as in steps 3 and 3 above.
- the hydrolysis of epoxy to dallicol is carried out in the same manner as in the above-mentioned steps 5A, 5B, 5C, 5D, for example.
- the conversion to the 24-position carboxyl group by oxidative cleavage of daricol can be carried out, for example, by the same method as in Steps 6A and 6C.
- the organic chemistry can generally be applied by the buyer's Billiger oxidation method using peracid, for example, the above-mentioned steps 3A, 3 Can be implemented in the same way as B .
- any of the above substrates can be oxidatively cleaved by direct ozone oxidation of the double bond at the 24-position to induce the 24-position aldehyde form or the 24-position carboxyl form.
- steroid compounds with 22 or more carbon atoms produced from carbohydrates by fermentation include timosterol monole, cholesta-7,24-gen-3i3-ol, cholesta-5,7,24-triene-3 -All, Desmostero Norre, Fucostello Norre, Epistello Norre, Elgosta-5, 1, 24 (28) -Trienol, Ergosta-5, 7, 22, 24 (28) -Tetraenols, Ergosterol, etc. be able to.
- These compounds include, for example, a step of constructing 5] 3 stereo 'by reductive saturation of the 4-position double bond by the same method as in Steps 4A and 4B, and if necessary, (I) 3-position A step of isomerizing a hydroxyl group with an acid group and a 5-position double bond to the 4-position; (II) a step of converting the side chain into a forcel l-poxyl group or its ester derivative by oxidative cleavage of the side chain; (III) By combining the step of introducing an oxygen functional group at the 7-position, the above general formula (8), (2 1 a), (2 1 b), (21 c) or (2 I d) (where R 1 is a hydrogen atom or carbon number 1-6 alkyl groups are shown.
- the aqueous phase was separated and washed with saturated aqueous sodium hydrogen carbonate, washed with water, and 4 ml of water was added to the mixture solution (*: L) at 78 ml of peracid solution at 0.5 ml (0.53 mmo). 1) was added and stirred at 78 ° C for 0.5 hours, and then 0.5 per ml of peracid solution (0.53 mm o 1) was added and stirred at 78 ° C for 0.5 hours.
- the phases were separated and washed with saturated aqueous sodium hydrogen carbonate and water, and 4 ml of water was added. The same operation as * ⁇ was repeated twice for this mixture.
- Process 4 A 5 ⁇ -24, 2 5—Epoxycholester 3—one-one 7-ol (compound 6) production>
- Process 5A 5 -Colester 3—Production of one-on-one 7, 24, 25-triol (compound 7)>
- Process 6 A Production of 5 ⁇ -3, 7-dioxocoranoic acid (compound 8)>
- Example 4 1-1 Crude 6, 7: 24, 25-diepoxycholester 4-1-enon 3--one synthesized in the same manner as in Example 1 was adsorbed on silica gel column, and hexane-ethyl acetate mixed solution was used. Elution gave 0.080 g of crude 6,7-epoxycholester 4-ene 3 -one 24,25-diol. The yield was 80%, and the NMR shift value (S p pm) is shown below.
- Process 6 B Production of 5-24, 25-epoxycholester 3, 7-dione (compound 1 2)>
- Example 5-2 Crude compound synthesized according to 2-5 J3- 24, 25-Epoxycholester 3
- One-on-one 7-ol (Compound 6) 667 mg was dissolved in acetonitrile 5.4 ml, water 2.7 ml, and acetic acid 1.
- Example 1 2 Crude 5-24, 25-epoxycholester 3, 7-dione (compound 1 2) 4 1 9 mg obtained in Example 1 3 was hydrolyzed in the same manner as in Example 6-2. 10 mg of crude 5 j3 -cholester 3,7-dione 24,25-diol was obtained. The yield was 97%, and the NMR shift value ( ⁇ p pm) is shown below.
- Example 1 Crude 5 3-cholester 3, 7-dione 1 24, 25-diol (compound 1 3) 3 9 Omg obtained in 4 was dissolved in acetonitrile 6 ml 1, water 2.7 ml, Further, 0.17 ml of acetic acid was added, and 294 mg (1.23 mm o 1) of 60% calcium hypochlorite was added to this mixture at 10 ° C, and the mixture was stirred at 10 for 26.5 hours. It was.
- Step 7 6, 7:24, 25 5-diepoxycholester 4-en-one 3-one Production of compound 5)>
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05762068A EP1775304A4 (en) | 2004-07-13 | 2005-07-12 | PROCESS FOR THE PRODUCTION OF STEROIDS |
CA002573613A CA2573613A1 (en) | 2004-07-13 | 2005-07-12 | A method for producing a steroid compound |
US11/264,035 US20060252948A1 (en) | 2004-07-13 | 2005-11-02 | Production method of steroid compound |
IL180498A IL180498A0 (en) | 2004-07-13 | 2007-01-02 | Process for production of steroids |
US12/827,902 US20110009615A1 (en) | 2004-07-13 | 2010-06-30 | Method for producing a steroid compound |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-205515 | 2004-07-13 | ||
JP2004205515 | 2004-07-13 | ||
JP2004-215304 | 2004-07-23 | ||
JP2004215304 | 2004-07-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/264,035 Continuation-In-Part US20060252948A1 (en) | 2004-07-13 | 2005-11-02 | Production method of steroid compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006006718A1 true WO2006006718A1 (ja) | 2006-01-19 |
Family
ID=35784044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/013216 WO2006006718A1 (ja) | 2004-07-13 | 2005-07-12 | ステロイド化合物の製造方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20060252948A1 (ja) |
EP (1) | EP1775304A4 (ja) |
KR (1) | KR20070067078A (ja) |
CA (1) | CA2573613A1 (ja) |
IL (1) | IL180498A0 (ja) |
TW (1) | TW200609245A (ja) |
WO (1) | WO2006006718A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007080951A1 (ja) * | 2006-01-12 | 2007-07-19 | Mitsubishi Chemical Corporation | ステロイド化合物の製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102516343A (zh) * | 2011-11-10 | 2012-06-27 | 长春市蜂谛园科技开发有限责任公司 | 新型抗肿瘤化合物人参皂苷Rh2衍生物及其制备 |
GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
CN111072744B (zh) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成熊去氧胆酸的方法 |
AU2021328142A1 (en) | 2020-08-21 | 2023-03-16 | Sandhill One, Llc | Methods of making cholic acid derivatives and starting materials therefor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0230085A1 (en) * | 1986-01-09 | 1987-07-29 | BLASCHIM S.p.A. | Stereoselective reduction of the keto group at 7-position of a bile keto acid |
JPH08165297A (ja) * | 1994-12-13 | 1996-06-25 | Fuji Chem Ind Co Ltd | エルゴステロール類縁体 |
US20020120111A1 (en) * | 2000-03-27 | 2002-08-29 | Sunghwa Choe | Dwf5 mutants |
WO2002088166A1 (en) * | 2001-05-02 | 2002-11-07 | Novo Nordisk A/S | Preparation of bile acids |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2984678A (en) * | 1956-12-11 | 1961-05-16 | Pfizer & Co C | 14alpha-hydroxy hydrocortisone, cortisone and derivatives |
US5460949A (en) * | 1990-11-15 | 1995-10-24 | Amoco Corporation | Method and composition for increasing the accumulation of squalene and specific sterols in yeast |
US6653492B2 (en) * | 2001-05-02 | 2003-11-25 | Novo Nordick A/S | Preparation of bile acids |
JP2007210888A (ja) * | 2006-01-12 | 2007-08-23 | Mitsubishi Chemicals Corp | ステロイド化合物の製造方法 |
-
2005
- 2005-07-12 EP EP05762068A patent/EP1775304A4/en not_active Withdrawn
- 2005-07-12 CA CA002573613A patent/CA2573613A1/en not_active Abandoned
- 2005-07-12 KR KR1020077003346A patent/KR20070067078A/ko not_active Application Discontinuation
- 2005-07-12 WO PCT/JP2005/013216 patent/WO2006006718A1/ja active Application Filing
- 2005-07-13 TW TW094123769A patent/TW200609245A/zh unknown
- 2005-11-02 US US11/264,035 patent/US20060252948A1/en not_active Abandoned
-
2007
- 2007-01-02 IL IL180498A patent/IL180498A0/en unknown
-
2010
- 2010-06-30 US US12/827,902 patent/US20110009615A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0230085A1 (en) * | 1986-01-09 | 1987-07-29 | BLASCHIM S.p.A. | Stereoselective reduction of the keto group at 7-position of a bile keto acid |
JPH08165297A (ja) * | 1994-12-13 | 1996-06-25 | Fuji Chem Ind Co Ltd | エルゴステロール類縁体 |
US20020120111A1 (en) * | 2000-03-27 | 2002-08-29 | Sunghwa Choe | Dwf5 mutants |
WO2002088166A1 (en) * | 2001-05-02 | 2002-11-07 | Novo Nordisk A/S | Preparation of bile acids |
Non-Patent Citations (5)
Title |
---|
CELDES AM ET AL: "NOVEL STEROLS FROM THE SPONGE ESPERIOPSIS EDWARD II.", TETRAHEDRON., vol. 44, no. 5, 1988, pages 1359 - 1362, XP002992095 * |
CRABB TA ET AL: "Microbiological transformations. Part 7. Microbiological transformations of A-nor-and A-homo-5 alpha-androstane derivatives with the fungus Cunninghamella elegans.", J OF CHEMICAL RESEARCH SYNOPSES., vol. 2, 1986, pages 48 - 49, XP002992094 * |
MCMORRIS TC ET AL: "Improved Synthesis of 24-Epibrassinolide from Ergosterol.", J ORG CHEM., vol. 58, no. 8, 1993, pages 2338 - 2339, XP002992093 * |
See also references of EP1775304A4 * |
TOCHTROP G P ET AL: "Synthesis of [3, 4-(13) c (2)]-Enriched Bile Salts as NMR Probes of Protein-Ligand Interactions.", J OF ORGANIC CHEMISTRY., vol. 67, no. 19, 2002, pages 6764 - 6771, XP002260968 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007080951A1 (ja) * | 2006-01-12 | 2007-07-19 | Mitsubishi Chemical Corporation | ステロイド化合物の製造方法 |
EP1985621A1 (en) * | 2006-01-12 | 2008-10-29 | Mitsubishi Chemical Corporation | Process for production of steroids |
EP1985621A4 (en) * | 2006-01-12 | 2010-05-19 | Mitsubishi Chem Corp | PROCESS FOR PRODUCING STEROIDS |
Also Published As
Publication number | Publication date |
---|---|
CA2573613A1 (en) | 2006-01-19 |
EP1775304A4 (en) | 2010-04-28 |
KR20070067078A (ko) | 2007-06-27 |
US20060252948A1 (en) | 2006-11-09 |
US20110009615A1 (en) | 2011-01-13 |
TW200609245A (en) | 2006-03-16 |
IL180498A0 (en) | 2007-06-03 |
EP1775304A1 (en) | 2007-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007080951A1 (ja) | ステロイド化合物の製造方法 | |
EP2766381B1 (en) | Process for preparing 17-substituted steroids | |
JPS5865299A (ja) | 3β,7β,15α―トリヒドロキシ―5―アンドロステン―17―オン又はその3、15―ジピバレート及びそれらの製造法 | |
JP4971179B2 (ja) | 17−ヒドロキシ−6β,7β;15β,16β−ビスメチレン−3−オキソ−17α−プレグネ−4−エン−21−カルボン酸γ−ラクトンの工業的製造方法およびこの方法のための重要中間体 | |
TWI280133B (en) | Process for preparing C-7 substituted steroids | |
WO2006006718A1 (ja) | ステロイド化合物の製造方法 | |
Jung et al. | First total synthesis of xestobergsterol A and active structural analogues of the xestobergsterols | |
CN101434632B (zh) | 一种3α,7α-二羟基-5β-胆烷酸的制备方法 | |
CN101374854A (zh) | 甾类化合物的制备方法 | |
Chen et al. | An effective synthesis of ursodeoxycholic acid from dehydroepiandrosterone | |
CN110172078B (zh) | 19羟化可托多松衍生物及19-羟基雄烯二酮的制备方法 | |
Iglesias-Arteaga et al. | The Baeyer-Villiger reaction of 23-oxosapogenins | |
JP3535588B2 (ja) | ジンセノサイドRh2の製造方法 | |
Barton et al. | Functionalisation of saturated hydrocarbons. Part 6. Selective oxidation of steroids and related compounds | |
CN101018802A (zh) | 甾类化合物的制备方法 | |
Zhang et al. | Stereoselective construction of a steroid 5α, 7α-oxymethylene derivative and its use in the synthesis of eplerenone | |
Salvador et al. | One-pot, high yield synthesis of α-ketols from Δ5-steroids | |
JP2006056877A (ja) | ステロイド化合物の製造方法 | |
Kurosawa et al. | Synthesis of 3α, 7α, 12α-trihydroxy-and 3α, 7α-dihydroxy-5β-cholestan-26-oic acids by the use of β-ketosulfoxide | |
JP2004307390A (ja) | ステロイド化合物の製造方法 | |
Gao et al. | Cyclocholates with 12‐oxo and 7, 12‐oxo groups | |
Musumeci et al. | The oxidation of Δ2, Δ2, 4 and Δ4, 6 steroids with RuO4 | |
TW200525036A (en) | Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters | |
US2840572A (en) | Chemical compounds and processes for preparing the same | |
RU2418805C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ НОВЫХ 3β-АЦЕТОКСИ-17α-ГИДРОПЕРОКСИ-16α-МЕТИЛПРЕГНАНОВ ИЗ Δ16-20-КЕТОСТЕРОИДОВ И СПОСОБ ПОЛУЧЕНИЯ 3β-АЦЕТОКСИ-17α-ГИДРОКСИ-16α-МЕТИЛПРЕГНАНОВ С ИСПОЛЬЗОВАНИЕМ 3β-АЦЕТОКСИ-17α-ГИДРОПЕРОКСИ-16α-МЕТИЛПРЕГНАНОВ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 11264035 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 11264035 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 180498 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2573613 Country of ref document: CA Ref document number: 127/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005762068 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077003346 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580030630.2 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005762068 Country of ref document: EP |